Eterna Therapeutics Inc
(NAS:ERNA)
$
1.94
-0.0265 (-1.35%)
Market Cap: 10.50 Mil
Enterprise Value: 52.83 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 20/100 - Eterna Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2023
- Eterna Therapeutics Inc Annual Shareholders Meeting TranscriptSep 21, 2022
- Brooklyn Immunotherapeutics Inc Annual Shareholders Meeting TranscriptJun 07, 2022
- Brooklyn Immunotherapeutics Inc at Benzinga Global Small Cap Investor Conference (Virtual) TranscriptDec 08, 2021
- Q1 2020 NTN Buzztime Inc Earnings Call TranscriptMay 19, 2020Earnings
- Q4 2019 NTN Buzztime Inc Earnings Call TranscriptMar 17, 2020Earnings
- Q3 2019 NTN Buzztime Inc Earnings Call TranscriptOct 30, 2019Earnings
- Q2 2019 NTN Buzztime Inc Earnings Call TranscriptAug 09, 2019Earnings
- Q1 2019 NTN Buzztime Inc Earnings Call TranscriptMay 13, 2019Earnings
- Q4 2018 NTN Buzztime Inc Earnings Call TranscriptMar 20, 2019Earnings
Brooklyn Immunotherapeutics Inc at Benzinga Global Small Cap Investor Conference (Virtual) Transcript
Dec 08, 2021 / 09:40PM GMT
Release Date Price:
$118.8
(+1.19%)
Spencer Israel
Benzinga - Managing Editor
Let's keep the show moving here. We got a couple presentations left. There is our next speaker; he's already here. Dr. Howard Federoff, he is the CEO of ImmunoTherapeutics. How are we doing today, sir?
Howard Federoff
Brooklyn ImmunoTherapeutics, Inc. - CEO
Great. How are you, Spencer?
Spencer Israel
Benzinga - Managing Editor
I'm doing well. It's Wednesday, which means we're over the hump coming down to the back half of the week. Take us home, Howard.
Howard Federoff
Brooklyn ImmunoTherapeutics, Inc. - CEO
All right. It's my pleasure. It's great to be with you.
Spencer Israel
Benzinga - Managing Editor
All right.
Howard Federoff
Brooklyn ImmunoTherapeutics, Inc. - CEO
So today, I'm going to be talking about an approach that probably is familiar, but let me start by recognizing our exceptional management team, many of whom have
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)